Organogenesis Holdings Inc. (ORGO)

Market Cap	519.80M
Revenue (ttm)	461.42M
Net Income (ttm)	13.48M
Shares Out	131.26M
EPS (ttm)	0.11
PE Ratio	36.00
Forward PE	12.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	960,005
Open	3.68
Previous Close	3.68
Day's Range	3.68 - 3.99
52-Week Range	1.80 - 6.52
Beta	1.43
Analysts	Strong Buy
Price Target	10.00 (+152.53%)
Earnings Date	May 10, 2023

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that prod...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 1,030
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO

Financial Performance

In 2022, ORGO's revenue was $450.89 million, a decrease of -3.52% compared to the previous year's $467.36 million. Earnings were $15.53 million, a decrease of -83.51%.

Analyst Forecast

According to one analyst, the rating for ORGO stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(152.53% upside)

Analyst Consensus: Strong Buy